Answers are grounded in this paper and cite their sources.
Transthyretin amyloid cardiomyopathy (ATTR-CM) has emerged as an increasingly identified etiology of heart failure. Fortunately, the disease now has an approved therapy, with many others under development. Assessment of prognosis in ATTR-CM is critical to inform patients about the disease course and guide clinical decisions. This review discusses the evidence behind clinical, biomarker, and imaging findings that inform prognosis in patients with ATTR-CM and can assist providers in the shared decision-making process during management of this disease.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: